Literature DB >> 11791159

Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia.

J H Thakore1, J N Mann, I Vlahos, A Martin, R Reznek.   

Abstract

OBJECTIVE: To investigate visceral fat distribution in patients with schizophrenia.
DESIGN: Cross sectional study using CT scanning in patients with drug-naive and drug-free schizophrenia.
SUBJECTS: Fifteen (13 men and two women) subjects with schizophrenia (mean age 33.7 y; mean body mass index (BMI)=26.7 kg/m(2)), and 15 age- and sex-matched controls (mean age 30.5 y; mean BMI=22.8 kg/(2)). MEASUREMENTS: Various fatness and fat distribution parameters (by CT scanning and anthropometry) and 16:00 h plasma cortisol.
RESULTS: In comparison to controls, patients with schizophrenia had central obesity and had significantly higher levels of plasma cortisol. Furthermore, previous neuroleptic exposure did not appear to influence these findings as both drug-naive and drug-free patients had equally high levels of visceral fat deposition.
CONCLUSION: Central obesity is a well recognized risk factor in developing certain general medical conditions. This study shows that patients with schizophrenia have increased intra-abdominal fat which may provide one explanation for why they die prematurely.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11791159     DOI: 10.1038/sj.ijo.0801840

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  56 in total

Review 1.  Pharmacogenetics of antipsychotic-induced weight gain.

Authors:  Christoph U Correll; Anil K Malhotra
Journal:  Psychopharmacology (Berl)       Date:  2004-07-08       Impact factor: 4.530

2.  Patients with Schizophrenia Do Not Demonstrate Worse Outcome After Sleeve Gastrectomy: a Short-Term Cohort Study.

Authors:  Rami Archid; Nicole Archid; Tobias Meile; Jonas Hoffmann; Julia Hilbert; Daniel Wulff; Martin Teufel; Michaela Muthig; Markus Quante; Alfred Königsrainer; Jessica Lange
Journal:  Obes Surg       Date:  2019-02       Impact factor: 4.129

Review 3.  Antipsychotic drugs and diabetes--an application of the Austin Bradford Hill criteria.

Authors:  R I G Holt; R C Peveler
Journal:  Diabetologia       Date:  2006-05-13       Impact factor: 10.122

4.  Barriers and facilitators of a healthy lifestyle among persons with serious and persistent mental illness: perspectives of community mental health providers.

Authors:  Christine L McKibbin; Katherine A Kitchen; Thomas L Wykes; Aaron A Lee
Journal:  Community Ment Health J       Date:  2014-07

5.  Exploring mechanisms of increased cardiovascular disease risk with antipsychotic medications: Risperidone alters the cardiac proteomic signature in mice.

Authors:  Megan Beauchemin; Ramaz Geguchadze; Anyonya R Guntur; Kathleen Nevola; Phuong T Le; Deborah Barlow; Megan Rue; Calvin P H Vary; Christine W Lary; Katherine J Motyl; Karen L Houseknecht
Journal:  Pharmacol Res       Date:  2019-12-23       Impact factor: 7.658

6.  Metabolic Effects of Antidepressant Treatment.

Authors:  Özlem Olguner Eker; Saliha Özsoy; Baki Eker; Hatice Doğan
Journal:  Noro Psikiyatr Ars       Date:  2017-03-01       Impact factor: 1.339

7.  S100B Serum Levels in Schizophrenia Are Presumably Related to Visceral Obesity and Insulin Resistance.

Authors:  Johann Steiner; Aye Mu Myint; Kolja Schiltz; Sabine Westphal; Hans-Gert Bernstein; Martin Walter; Matthias L Schroeter; Markus J Schwarz; Bernhard Bogerts
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-06-10

8.  The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats.

Authors:  Martina von Wilmsdorff; Marie-Luise Bouvier; Uwe Henning; Andrea Schmitt; Wolfgang Gaebel
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

Review 9.  Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?

Authors:  Hiram Joseph Wildgust; Mike Beary
Journal:  J Psychopharmacol       Date:  2010-11       Impact factor: 4.153

10.  A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.

Authors:  H Y Chan; C J Chang; S C Chiang; J J Chen; C H Chen; H J Sun; H G Hwu; M S Lai
Journal:  J Psychopharmacol       Date:  2008-09-18       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.